These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31255662)

  • 1. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.
    Alexopoulos AS; Buse JB
    Metabolism; 2019 Sep; 98():104-111. PubMed ID: 31255662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
    Huthmacher JA; Meier JJ; Nauck MA
    Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
    Carris NW; Taylor JR; Gums JG
    Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
    Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
    Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice.
    Romera I; Rubio-de Santos M; Artola S; Suárez Fernández C; Conget I
    Adv Ther; 2023 Apr; 40(4):1418-1429. PubMed ID: 36821026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
    Schechter M; Melzer Cohen C; Fishkin A; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Chodick G; Clark A; Abrahamsen TJ; Lawson J; Karasik A; Mosenzon O
    Cardiovasc Diabetol; 2023 May; 22(1):126. PubMed ID: 37244998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
    Perreault L; Rodbard H; Valentine V; Johnson E
    Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
    Handelsman Y; Wyne K; Cannon A; Shannon M; Schneider D
    J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S14-S29. PubMed ID: 30156445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
    Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.